tirzepatide fda label Grants a New Indication for Obesity Management Ozempic, Wegovy, and Mounjaro: Prescribing
Description
Discover the prevalence of semaglutide for weight loss, its side effects, and its marketstatistics.
Concierge medical weight loss (GLP-1) and peptide therapy telehealth in all 50 states
A recent study from the Mayo Clinic reveals that postmenopausal women undergoing hormone therapy experience significantly more weight loss when treated with semaglutide, a popular anti-obesity drug, compared to those not on hormone therapy
While this doesnt negate their metabolic benefits, it highlights a crucial aspect of long-term patient care
